Information on the total number of voting rights (denominator) following the conversion notice of NEGMA

Oxurion AG

The Negma group has converted 130 bonds convertible into Oxurion resulting in a EUR 325.000 increase in capital. This is part of Negma Group’s €30m capital commitment1 which will allow Oxurion to focus on advancing its new differentiated drug for the back of the eye candidate targeting potential market opportunities over USD 5 billion.

Leuven, BELGIUM, Boston, MA, USA November 11, 2022 – 0seven.00 PM CET – In accordance with article 15 of the Belgian law of May 2, 2007 relating to the publication of major holdings in issuers whose shares are admitted to trading on a regulated market and with the various provisions, Oxurion AG (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the information below, following the issue of 16,250,000 new ordinary shares on November 7, 2022, for a total amount of EUR 325,000, continued the conversion of 130 class B convertible bonds, as part of the Capital Commitment entered into with Negma Group.

Following the completion of the capital increase by conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 109,075,765 ordinary shares in circulation with voting rights (compared to 92,825,765 ordinary shares in circulation previously ). This number will serve as the denominator for the calculation of the participation percentages.

Therefore, Oxurion publishes the following updated information:

72,981,161.32

109 075 765

109 075 765

  • 719,500 subscription rights (“PD”) issued on November 20, 2017, entitling their holders to subscribe for a total number of 719,500 securities carrying voting rights (all ordinary shares);

  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);

  • 1,007,250 SRs issued on April 14, 2021, entitling their holders to subscribe for a total number of 1,007,250 securities carrying the right to vote (all ordinary shares);

  • 550,000 SRs issued on September 22, 2021, entitling their holders to subscribe for a total number of 550,000 securities with voting rights (all ordinary shares);

  • 725,749 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 725,749 securities carrying voting rights (all ordinary shares);

  • 810 convertible bonds issued on September 5, 2022 and October 21, 2022, entitling their holder (Negma Group) to subscribe to a total number of securities with voting rights (all ordinary shares) according to the terms and conditions provided for in the issue and subscription agreement entered into between the Company and Negma Group on August 26, 2021 and its amendment dated September 2, 2022; and

  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) LP and Pontifax Medison Finance (Cayman) LP) to subscribe to a total number of securities carrying vote (all ordinary shares) in accordance with the terms and conditions of such convertible bonds as attached to the agreement for the provision of a loan facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) LP and Pontifax Medison Finance (Cayman) LP, November 21, 2021.

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation ophthalmic therapies designed to improve and better preserve vision in patients with retinal disorders, including diabetic macular edema (DME), the leading cause of vision loss. view among workers. -elderly, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic product for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for up to 50% of DME patients with a suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements contained in this press release may be considered “forward-looking”. These forward-looking statements are based on current expectations and, therefore, involve and are influenced by various risks and uncertainties. The Company therefore cannot guarantee that these forward-looking statements will materialize and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or for any other reason. Additional information regarding risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statements can be found in the company’s annual report. This press release does not constitute an offer or an invitation to sell or buy any securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption therefrom, and pursuant to applicable U.S. securities laws movables.

For more information, please contact:

1 Oxurion press release, 06/04/2021 and Oxurion press release, 02/09/2022

Attachment

Comments are closed.